加强关系维护、更安全受孕和 PrEP 方面的沟通,以促进乌干达的艾滋病毒检测
Our novel communication strategy aims to promote HIV testing in Uganda with reassuring messages about the ability to have stable relationships and healthy families with the increased availability of pre-exposure prophylaxis (PrEP). We will evaluate the feasibility and acceptability of this communication strategy among clients and partners within assisted partner notification and antenatal care programs in two hospitals and evaluate preliminary effects.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
Optimizing uptake of HIV testing is critical to meeting 95-95-95 goals in sub-Saharan Africa. As 30% of new infections in occur within married or cohabitating couples, maximizing testing among individuals who are or may someday be in serious heterosexual relationships has been identified as one of the most cost-effective strategies to curb the epidemic. Childbearing is highly valued throughout Sub-Saharan Africa, and fears of relationship dissolution and loss of the ability to have children remain significant barriers to HIV testing. The expanding availability of pre-exposure prophylaxis (PrEP) presents an opportunity to counter these fears with strategic communication (NOT-MH-21-105) that reassure couples of their ability to have a healthy family even if one or both members are HIV positive. Our long-term objective is to leverage the growing availability of PrEP to determine if and how a communication strategy focused on relationship preservation and safer conception can increase testing and entry into treatment (antiretroviral therapy) or prevention (PrEP) among partnered individuals in Uganda. We recently successfully piloted this communication strategy within Uganda's assisted partner notification program (APN). In this R34, we will: (1) conduct formative research to expand the communication strategy into a multi-component intervention with broader reach; and (2) conduct a pilot trial of the intervention, PrEPing Healthy Families. To achieve Aim 1, we will work with a community advisory board (CAB) of providers to a) create communication materials (brochures, scripts) and counseling protocols tailored to clients and partners across the array of couples' testing pathways in APN and antenatal care (ANC). As CAB providers pilot materials and tracking systems with clients and partners during this development phase, study staff will conduct field observations and qualitative interviews focused on feasibility and acceptability, informing revised intervention materials. To achieve Aim 2, we will collect baseline data at APN and ANC clinics within two large public healthcare facilities over nine months. Sites will then be randomized to implement PrEPing Healthy Families or their existing communication approach (usual care) over the next nine months. We will collect mixed-methods data on feasibility and acceptability through intervention tracking in APN/ANC registers, client exit surveys, and qualitative interviews with clients, partners and providers. Through register extraction, we will examine limited efficacy on outcomes that would be relevant to a larger trial (partner HIV testing, client service uptake initiation of PrEP/ART), and explore potential moderators. Overall, results will yield important insights in a promising new communication strategy (NOT-MH-21-105) that may connect more individuals to the HIV cascades of care for treatment or prevention and prepare us for a large-scale, cluster randomized controlled trial to determine impact on testing and initiation of PrEP/ART.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Gombe、乌干达
- Gombe Hospital
-
Mityana、乌干达
- Mityana Hospital
-
-
参与标准
资格标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Client or partner of client receiving antenatal or assisted partner notification services at one of two study hospitals (Gombe Hospital or Mityana Hospital)
Exclusion Criteria:
- Individuals under the age of 18 years (for interviews and surveys only)
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Communication intervention "HOPE"
|
|
|
无干预:Usual care
Usual care |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Rate of HIV Testing (Male Partners of Antenatal Care Patients)
大体时间:7 month baseline period (Sept 2023- March 2024) and 7 month intervention period (Sept 2024- March 2025)
|
We used register extraction of standard ANC clinic registers to determine testing status of male partners of each patient who had an ANC visit during the baseline and intervention periods. We excluded those indicating the male partner was not recommended for HIV testing (known HIV negative from previous test during this pregnancy; known HIV positive from previous test during this pregnancy; known HIV positive determined prior to first ANC visit; known HIV negative according to test conducted within 4 weeks prior to first ANC visit). Successful testing as a composite outcome included partners who tested for the first time (positive or negative) or completed a re-test following a negative test earlier in the pregnancy (recommended after 3 months). |
7 month baseline period (Sept 2023- March 2024) and 7 month intervention period (Sept 2024- March 2025)
|
|
Change in Rate of HIV Testing Among Partners of Assisted Partner Notification (APN) Program
大体时间:7 month baseline period and 7 month intervention period
|
APN partner testing was extracted from standard clinic registers. We excluded partners who were known to be HIV positive or deceased. Our analysis examined the portion of APN partners recommended for testing who presented at the hospital for testing. |
7 month baseline period and 7 month intervention period
|
合作者和调查者
合作者
合作者
调查人员
调查人员
- 首席研究员:Emily Hurley, PhD、Children's Mercy Kansas City
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
其他研究编号
- STUDY00002400
- 5R34MH132473 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified dataset and other materials will be made available to individual researchers upon reasonable request.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.